<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04083950</url>
  </required_header>
  <id_info>
    <org_study_id>FL109</org_study_id>
    <nct_id>NCT04083950</nct_id>
  </id_info>
  <brief_title>Induction of Gut Permeability by an Oral Vaccine</brief_title>
  <official_title>Induction of Gut Permeability by an Oral Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>USDA, Western Human Nutrition Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>USDA, Western Human Nutrition Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the effect of an oral typhoid vaccine on disruption of the intestinal&#xD;
      barrier and response of the immune system. Intestinal and whole-body responses will be&#xD;
      measured in all participants before and after the vaccine.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The licensed Ty21a vaccine strain of S. enterica Typhi is routinely used by travelers to&#xD;
      countries where typhoid is common. It is not known whether the vaccine causes measurable&#xD;
      changes in intestinal permeability and whether changes in permeability are correlated with&#xD;
      the magnitude of the vaccine response. In the current study, gut permeability will be&#xD;
      measured in participants at baseline and after an aspirin challenge, which is known to&#xD;
      disrupt intestinal permeability, and after the first, second, and fourth doses of a the Ty21a&#xD;
      vaccine. Intestinal permeability will be measured using a three-sugar absorption test&#xD;
      composed of lactulose, mannitol, and sucralose and by several plasma markers. Vaccine&#xD;
      response will be measured by quantitating T cells and newly developed IgG-or IgA-secreting&#xD;
      plasma cells specific for Ty21a.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 4, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in intestinal permeability</measure>
    <time_frame>Day 1, 3, 16, 18, and 22</time_frame>
    <description>Measurement of sugar (lactulose, D-mannitol, and sucralose) excretion in urine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibody response to typhoid vaccination</measure>
    <time_frame>Day 1, 18, 22, 24, and 29</time_frame>
    <description>Measurement of Typhi-specific immunoglobulin G (IgG) and immunoglobulin A (IgA) plasma cells in peripheral blood using the antibody in lymphocyte supernatant assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T-cell response to typhoid vaccination</measure>
    <time_frame>Day 1, 22, and 29</time_frame>
    <description>Measurement of vaccine-specific cluster of differentiation 4 (CD4) and cluster of differentiation 8 (CD8) T-cells in peripheral blood mononuclear cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in markers of inflammation</measure>
    <time_frame>Day 1, 3, 16, 18, 22, and 24</time_frame>
    <description>Measurement of plasma cytokines, chemokines, and acute phase proteins by a multiplex immunoassay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intestinal fatty acid binding protein (iFABP)</measure>
    <time_frame>Day 1, 3, 16, 18, and 22</time_frame>
    <description>Measurement of plasma iFABP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D-lactate</measure>
    <time_frame>Day 1, 3, 16, 18, and 22</time_frame>
    <description>Measurement of plasma D-lactate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in diamine oxidase</measure>
    <time_frame>Day 1, 3, 16, 18, and 22</time_frame>
    <description>Measurement of plasma diamine oxidase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipopolysaccharide binding protein (LBP)</measure>
    <time_frame>Day 1, 3, 16, 18, and 22</time_frame>
    <description>Measurement of plasma LBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in citrulline</measure>
    <time_frame>Day 1, 3, 16, 18, and 22</time_frame>
    <description>Measurement of plasma citrulline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Intestinal Permeability</condition>
  <condition>Inflammation</condition>
  <condition>Vaccine</condition>
  <condition>Typhoid Fever</condition>
  <arm_group>
    <arm_group_label>Single group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All participants will receive the vaccine and aspirin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vivotif Typhoid Oral Vaccine</intervention_name>
    <description>One capsule is swallowed on alternate days, e.g. days 15, 17, 19, and 21, for a total of 4 capsules.</description>
    <arm_group_label>Single group</arm_group_label>
    <other_name>Ty21a Typhoid Oral Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin (Positive Control)</intervention_name>
    <description>Three tablets (325 mg aspirin in each tablet or 975 mg total) are swallowed on days 2 and 3.</description>
    <arm_group_label>Single group</arm_group_label>
    <other_name>Aspirin Challenge</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) 18.5 - 29.9 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has HIV/AIDS or another disease that affects the immune system&#xD;
&#xD;
          -  Has any kind of cancer&#xD;
&#xD;
          -  Decline to take an HIV blood test&#xD;
&#xD;
          -  Blood pressure greater than or equal to 140/90 mmhg&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Refusal to take a pregnancy test prior to the study&#xD;
&#xD;
          -  Refusal to use a method of birth control during the study&#xD;
&#xD;
          -  Allergy to vaccine components, i.e. Thimerosal and enteric-coated capsules&#xD;
&#xD;
          -  Allergy to oral typhoid vaccine&#xD;
&#xD;
          -  Allergy to aspirin&#xD;
&#xD;
          -  Daily use of blood thinners&#xD;
&#xD;
          -  Use of anti-inflammatory medications, i.e. nonsteroidal anti-inflammatory drugs&#xD;
             (NSAID), aspirin, 3 or more times per month&#xD;
&#xD;
          -  Use of sulfonamides or antibiotics in the past 30 days&#xD;
&#xD;
          -  Use of anti-hypertensive drugs, i.e. beta blockers, diuretics, calcium channel&#xD;
             blockers&#xD;
&#xD;
          -  Use of anti-malaria drugs, i.e. Mefloquine, chloroquine, and proguanil&#xD;
&#xD;
          -  Use of drugs that affect the immune system, i.e. immunosuppressants, immune-modifying&#xD;
             drugs, corticosteroids, i.e. cortisone, prednisone, methylprednisolone, for 2 weeks or&#xD;
             longer&#xD;
&#xD;
          -  Is taking cancer treatment with radiation or drugs&#xD;
&#xD;
          -  Greater than ten years residence in a typhoid-endemic area&#xD;
&#xD;
          -  Receipt of typhoid vaccine in the last 5 years&#xD;
&#xD;
          -  Receipt of any vaccine two weeks prior to receipt of Ty21a vaccine&#xD;
&#xD;
          -  Individuals at increased risk of developing complications from a live, bacterial&#xD;
             vaccine&#xD;
&#xD;
          -  History of typhoid fever&#xD;
&#xD;
          -  History of primary immune deficiency or autoimmune disease&#xD;
&#xD;
          -  History of acute or chronic gastrointestinal (GI) disorder, i.e. Crohn's disease,&#xD;
             irritable bowel syndrome, gastric ulcer&#xD;
&#xD;
          -  Diarrheal illness (defined as passing 3 or more abnormally loose or watery stool in a&#xD;
             24 hour period) or persistent vomiting 2 weeks prior to the study&#xD;
&#xD;
          -  History of bleeding disorder, including bleeding from the GI tract&#xD;
&#xD;
          -  History of chronic illnesses, i.e. diabetes, cardiovascular disease, cancer,&#xD;
             gastrointestinal malabsorption or inflammatory diseases, kidney disease, autoimmune&#xD;
             disorders, HIV, liver disease, including hepatitis B and C.&#xD;
&#xD;
          -  Asthma if taking medication on a daily basis&#xD;
&#xD;
          -  Recent surgery (within 3 months)&#xD;
&#xD;
          -  History of GI surgery&#xD;
&#xD;
          -  Recent hospitalization (within 3 months)&#xD;
&#xD;
          -  Acute febrile illness (within 2 weeks)&#xD;
&#xD;
          -  Unwillingness to discontinue consumption of artificial sweeteners in foods or drinks,&#xD;
             i.e. sport drinks, coconut water, &quot;diet&quot; drinks and foods (possibly containing&#xD;
             sucralose)&#xD;
&#xD;
          -  Not having at least one arm vein suitable for blood drawing&#xD;
&#xD;
          -  Unwilling or uncomfortable with blood draws seven times in 29 days&#xD;
&#xD;
          -  Regular blood or blood product donation and refusal to suspend donation&#xD;
&#xD;
          -  Current participation in another research study&#xD;
&#xD;
          -  Unable to fast for 12-16 hours&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danielle Lemay, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USDA, ARS, Western Human Nutrition Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ellen Bonnel, PhD</last_name>
    <phone>530-752-4184</phone>
    <email>ellen.bonnel@usda.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuriko Adkins, PhD</last_name>
    <phone>530-752-9469</phone>
    <email>yuriko.adkins@usda.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>USDA, ARS, Western Human Nutrition Research Center</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen Bonnel, PhD</last_name>
      <phone>530-752-4184</phone>
      <email>ellen.bonnel@usda.gov</email>
    </contact>
    <contact_backup>
      <last_name>Yuriko Adkins, PhD</last_name>
      <phone>530-752-9469</phone>
      <email>yuriko.adkins@usda.gov</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 5, 2019</study_first_submitted>
  <study_first_submitted_qc>September 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2019</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastrointestinal Health</keyword>
  <keyword>Intestinal Permeability</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Vaccine Response</keyword>
  <keyword>Ty21a Typhoid Vaccine</keyword>
  <keyword>Typhoid Fever</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Typhoid Fever</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

